# Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05403385/  
OnCo record `nct05403385` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by iTeos Therapeutics, active and no longer recruiting.

## Summary

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05403385 by iTeos Therapeutics, with 36 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2025-06-13. Interventions recorded: inupadenant, Placebo, Carboplatin, Pemetrexed. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05403385
- Phase: 2
- Setting: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
- Sponsor: iTeos Therapeutics
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT05403385: https://clinicaltrials.gov/study/NCT05403385

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05403385.json